Novartis, Ionis Heart Drug Misses Phase 3 Goal Despite Cutting Lp(a)

Novartis and Ionis said pelacarsen lowered Lp(a) but failed to cut heart attacks, strokes or deaths in a Phase 3 trial of 8,323 patients.